The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.
On Tuesday, the antibiotic Xacduro was approved by the US Food and Drug Administration (FDA) to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii-calcoaceticus (ABC) in patients 18 years of age and older.
Xacduro (sulbactam-durlobactam; SUL-DUR) is an intravenous investigational therapy that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a novel broad-spectrum IV β-lactamase inhibitor. SUL-DUR targets ABC infections, including those caused by multidrug-resistant and carbapenem-resistant (CRAB) strains.
Contagion has been following this exciting new agent for a while and has compiled 5 of our most recent and relevant pieces of content. Dive into these clinical trials and interviews with experts to learn more about how Xacduro could be a game-changer in the fight against highly resistant pathogens.